Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.
The European Medicines Agency (EMA) has granted Orphan Drug Designation for cystic fibrosis to GY971, a new anti-inflammatory molecule developed by the Universities of Ferrara and Padua and the Azienda Ospedaliera Universitaria di Verona with funding from the Foundation for Cystic Fibrosis Research - ETS (FFC Ricerca).
Nasce il Premio Chiara Gemmo dedicato ai giovani ricercatori. L’iniziativa si propone di sostenere le nuove generazioni di scienziati.
[E]Motion: moving research
[E]Motion is the name of the challenging journey that Alessandro, a young man affected by the Usher Syndrome, will make together with Rare Partners, riding his tandem bike “Bike4Usher” in support of research for the Usher Syndrome.
